breast augmentation breast feeding
Adjuvant Treatment is the Best Option to Prevent Breast Cancer Recurrence
Beyond 215,000 women are clinically determined to have breast cancer every year. Basically, the breast cancer patients are not only given the surgical treatment, sometimes they have to go through chemotherapy or radiation therapy to totally eliminate the cancer. Subsequently, these women should decide with their medical doctor if they should have adjuvant therapy which is the treatment to help reduce their cancer from coming back. I think you would like to read Cancer Research and How to Prepare Radiation for Breast Cancer too.
When a woman's breast cancer does come back or spreads to other parts of the body, the woman could be at greater risk of dying from the disease. Women whose breast cancer is noticed in the nearby lymph nodes at diagnosis and those that acquire chemotherapy after surgical treatment are believed to be at higher risk for breast cancer recurrence.
Postmenopausal women whose early-stage breast cancer is hormone-sensitive have a new option as their first hormone therapy following surgery. The U.S. Food and Drug Administration recently recognized Femara (letrozole tablets) on December 28, 2005 for this type of use. This acceptance was based upon a median of 24 months of treatment. The investigation remains ongoing to look for the long-term safety and effectiveness of Femara. Already a leading breast cancer treatment, Femara has become the only medicine in a group called aromatase inhibitors which is recognized for use both right after surgical procedure and after five years of tamoxifen. The FDA granted Femara a high priority evaluation, a distinction reserved for medications which may probably offer a substantial development compared to products currently on the market.
A panel from the American Society of Clinical Oncology, the nation's primary group of oncologists, suggests aromatase inhibitors, including Femara, be part of the ideal adjuvant treatment for this group of women.
"One of the greatest concerns confronted by ladies who are actually medicated for early breast cancer is that their cancer will come back. With Femara, we now have a solution which can help address that worry early on, even in patients who we realize face the highest risk of recurrence," said Matthew Ellis, MD, PhD, FRCP, director of the Breast Cancer Program at Washington University in St. Louis.
In a very big clinical research of post-surgery breast cancer treatment, scientists compared the potency of Femara and tamoxifen, a different drug prescribed after surgery. An analysis conducted after 26 months showed that Femara decreased the risk of breast cancer coming back by 21% over the reduction offered by tamoxifen. Patients taking Femara also showed a 27 % decrease in the risk of the cancer spreading to distant parts of the body.
In this study, women at increased risk of recurrence experienced the best benefit from Femara. Femara decreased this risk by 29 % in females whose breast cancer had already metastasize towards the lymph nodes at the time of diagnosis and by 30 % in women who had prior chemotherapy. The results also showed that in these high-risk women, Femara lowered the risk of cancer spreading to distant parts of the body by 33 % and 31 %, respectively.
From the research above, we can see that the Femara treatment will not induce any bad effect to the patients. The side effects such as joint pain, weight gain and so on are really scary.
In conclusion, hopefully that Femara could possibly be solution for us to prevent the breast cancer recurrence. The secondary cancer may appear far more harmful compared to the primary cancer.
Access Hollywood Expert Opinion: Breast Augmentation and Breast Feeding
